Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Rouen
About this trial
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.
Eligibility criteria
Qualifiers
Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement).
Membership of a social security scheme
Adult having read and understood the information letter and signed the consent form
Disqualifiers
Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship
Trial design
Treatments tested in this trial
- Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov